Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.

Ann Neurol · 2022 · PMC9828339 · PMID 36151869

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

close to significancep < 0.1so close (0.05 < p ≤ 0.1)

Factors that were close to significance ( p < 0.1) or significantly associated with the risk of ARIA‐E were further evaluated using logistic regression with baseline age and EYO as covariates.

also in 2,130 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.